SETD2 and neoplasm: In addition, mTOR inhibitors can also impact angiogenesis by inhibiting the production of proangiogenic factors in tumors and tumor-associated stromal cells.29 Moreover, mTOR contributes in the hypoxic tumor response by stabilizing hypoxia-inducible factor-1α (HIF-1 α),30 hence it is not surprising that mTOR inhibitors can reduce VEGF expression and act as antiangiogenic agents.31